Search hospitals > Missouri > Kansas City
Children's Mercy Hospital
Claim this profileKansas City, Missouri 64108
Global Leader in Cancer
Global Leader in Leukemia
Conducts research for Neuroblastoma
Conducts research for Acute Lymphoblastic Leukemia
Conducts research for Brain Tumor
841 reported clinical trials
48 medical researchers
Summary
Children's Mercy Hospital is a medical facility located in Kansas City, Missouri. This center is recognized for care of Cancer, Leukemia, Neuroblastoma, Acute Lymphoblastic Leukemia, Brain Tumor and other specialties. Children's Mercy Hospital is involved with conducting 841 clinical trials across 1,085 conditions. There are 48 research doctors associated with this hospital, such as Keith J. August, Kevin F. Ginn, John Anderson, MD, and Mark Clements, MD, PhD.Area of expertise
1Cancer
Global LeaderStage IV
Stage I
Stage II
2Leukemia
Global LeaderNTRK1 positive
NTRK positive
ABL-class fusions positive
Top PIs
Keith J. AugustChildren's Mercy Hospitals and Clinics5 years of reported clinical research
Studies Neuroblastoma
Studies Cancer
54 reported clinical trials
112 drugs studied
Kevin F. GinnChildren's Mercy Hospitals and Clinics8 years of reported clinical research
Expert in Cancer
Expert in Neuroblastoma
36 reported clinical trials
58 drugs studied
John Anderson, MDClinical Research Center of Alabama5 years of reported clinical research
Studies Hereditary Angioedema
Studies Adolescent Idiopathic Scoliosis
9 reported clinical trials
11 drugs studied
Mark Clements, MD, PhDChildren's Mercy Hospital3 years of reported clinical research
Studies Type 1 Diabetes
Studies Diabetes Mellitus
7 reported clinical trials
14 drugs studied
Clinical Trials running at Children's Mercy Hospital
Neuroblastoma
Brain Tumor
Testicular cancer
Cancer
Wilms Tumor
Chronic Kidney Disease
Leukemia
Lazy Eye
Brain Cancer
Cystic Fibrosis
Lorlatinib + Standard Therapy
for Neuroblastoma
This phase III trial studies iobenguane I-131 or lorlatinib and standard therapy in treating younger patients with newly-diagnosed high-risk neuroblastoma or ganglioneuroblastoma. Radioactive drugs, such as iobenguane I-131, may carry radiation directly to tumor cells and not harm normal cells. Lorlatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving iobenguane I-131 or lorlatinib and standard therapy may work better compared to lorlatinib and standard therapy alone in treating younger patients with neuroblastoma or ganglioneuroblastoma.
Recruiting2 awards Phase 322 criteria
Dinutuximab + Chemotherapy
for High-Risk Neuroblastoma
This phase III trial tests how well the addition of dinutuximab to Induction chemotherapy along with standard of care surgical resection of the primary tumor, radiation, stem cell transplantation, and immunotherapy works for treating children with newly diagnosed high-risk neuroblastoma. Dinutuximab is a monoclonal antibody that binds to a molecule called GD2, which is found on the surface of neuroblastoma cells, but is not present on many healthy or normal cells in the body. When dinutuximab binds to the neuroblastoma cells, it helps signal the immune system to kill the tumor cells. This helps the cells of the immune system kill the cancer cells, this is a type of immunotherapy. When chemotherapy and immunotherapy are given together, during the same treatment cycle, it is called chemoimmunotherapy. This clinical trial randomly assigns patients to receive either standard chemotherapy and surgery or chemoimmunotherapy (chemotherapy plus dinutuximab) and surgery during Induction therapy. Chemotherapy drugs administered during Induction include, cyclophosphamide, topotecan, cisplatin, etoposide, vincristine, and doxorubicin. These drugs work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing or by stopping them from spreading. Upon completion of 5 cycles of Induction therapy, a disease evaluation is completed to determine how well the treatment worked. If the tumor responds to therapy, patients receive a tandem transplantation with stem cell rescue. If the tumor has little improvement or worsens, patients receive chemoimmunotherapy on Extended Induction. During Extended Induction, dinutuximab is given with irinotecan, temozolomide. Patients with a good response to therapy move on to Consolidation therapy, when very high doses of chemotherapy are given at two separate points to kill any remaining cancer cells. Following, transplant, radiation therapy is given to the site where the cancer originated (primary site) and to any other areas that are still active at the end of Induction. The final stage of therapy is Post-Consolidation. During Post-Consolidation, dinutuximab is given with isotretinoin, with the goal of maintaining the response achieved with the previous therapy. Adding dinutuximab to Induction chemotherapy along with standard of care surgical resection of the primary tumor, radiation, stem cell transplantation, and immunotherapy may be better at treating children with newly diagnosed high-risk neuroblastoma.
Recruiting2 awards Phase 37 criteria
Advanced Therapy
for Neuroblastoma
A prospective open label, multicenter study to evaluate the feasibility and acute toxicity of using molecularly guided therapy in combination with standard therapy followed by a Randomized Controlled Trial of standard immunotherapy with or without DFMO followed by DFMO maintenance for Subjects with Newly Diagnosed High-Risk Neuroblastoma.
Recruiting1 award Phase 23 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Children's Mercy Hospital?
Children's Mercy Hospital is a medical facility located in Kansas City, Missouri. This center is recognized for care of Cancer, Leukemia, Neuroblastoma, Acute Lymphoblastic Leukemia, Brain Tumor and other specialties. Children's Mercy Hospital is involved with conducting 841 clinical trials across 1,085 conditions. There are 48 research doctors associated with this hospital, such as Keith J. August, Kevin F. Ginn, John Anderson, MD, and Mark Clements, MD, PhD.
Where is Children's Mercy Hospital located?
Children's Mercy Hospital, headquartered at 2401 Gillham Road, Kansas City, MO 64108, offers comprehensive healthcare services across multiple locations. For urgent care needs, facilities are available in Overland Park, KS; Blue Valley, KS; East Independence, MO; West Kansas City, KS; Joplin, MO; Junction City, KS; and Wichita, KS. This network ensures accessible and specialized care for children throughout the region.
Who should I call to ask about financial aid or insurance network?
**Financial Assistance at Children's Mercy Hospital:**
- For financial assistance inquiries, contact the Admissions Financial Counseling department at admfc@cmh.edu or (816) 234-3567.
- For payment arrangements, reach out to Patient Financial Services at (816) 701-5100 or toll-free at (866) 572-0157.
- To apply, complete the online Financial Assistance Application or submit the printed form with proof of residency, pay stubs, and recent tax returns via mail, email, or fax.
What insurance does Children's Mercy Hospital accept?
Children's Mercy Hospital accepts a wide range of insurance plans, including commercial, Medicare, and Medicaid from various local and national carriers. The hospital offers the Children's Mercy Take CARE plan for its team members working at least 30 hours per week, with medical plans administered by Cigna, featuring the Gold, Blue, and Green Plans. It is crucial to verify coverage and restrictions with your insurance provider before scheduling visits to ensure services are covered.
What awards or recognition has Children's Mercy Hospital received?
Children's Mercy Hospital in Kansas City, Missouri, is renowned for its exceptional research and care efforts. It has been awarded the "Chronic Kidney Disease in Children" Study Award by the Children's Mercy Research Institute (CMRI), highlighting its commitment to improving children's health. Furthermore, the CMRI has achieved AAHRPP accreditation, demonstrating its dedication to quality and protection for participants in clinical studies, and the hospital is recognized as a Joy in Medicine™ organization by the American Medical Association (AMA).
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.